Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment.

We retrospectively studied the factors affecting the rate of hematopoietic reconstitution (HR) in 118 patients with hematological malignancies who underwent peripheral blood progenitor cell (PBPC) transplantation at a single institution. The patients received a median number of 6.6 x 10(8) nucleated cells/kg corresponding to 9.5 x 10(4) (0.5-578) CFU-GM/kg and 6.8 x 10(6) (0.2-161) CD34-positive cells/kg. The median number of days to reach 500 polymorphonuclear cells/mm3 and 50,000 platelets/mm3 was 12.5 (6-93) and 14.5 (6-440) days, respectively. No patient died from infection during the aplastic phase. By multivariate analysis, we found that the dose of CFU-GM infused was the only factor that significantly affects the HR rate (p < 0.0001). Moreover, patients with acute myelogenous leukemia or those transplanted after busulfan or total-body irradiation conditioning regimens had a slower engraftment (p < 0.08). These results could lead to identifying patients who need growth factors posttransplantation and/or the reinfusion of "back-up" marrow together with PBPC.
AuthorsJ Reiffers, C Faberes, J M Boiron, G Marit, C Foures, A M Ferrer, P Cony-Makhoul, M Puntous, P Bernard, G Vezon
JournalJournal of hematotherapy (J Hematother) Vol. 3 Issue 3 Pg. 185-91 ( 1994) ISSN: 1061-6128 [Print] UNITED STATES
PMID7530133 (Publication Type: Journal Article)
Chemical References
  • Antigens, CD
  • Antigens, CD34
  • Actuarial Analysis
  • Adolescent
  • Adult
  • Aged
  • Antigens, CD
  • Antigens, CD34
  • Child
  • Colony-Forming Units Assay
  • Female
  • Graft Survival
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia (mortality, therapy)
  • Lymphoma (mortality, therapy)
  • Male
  • Middle Aged
  • Multiple Myeloma (mortality, therapy)
  • Platelet Count
  • Retrospective Studies
  • Survival Rate
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: